Compare XPO & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPO | WAT |
|---|---|---|
| Founded | 2000 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 17.4B |
| IPO Year | N/A | 1995 |
| Metric | XPO | WAT |
|---|---|---|
| Price | $143.24 | $394.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | $147.17 | ★ $382.14 |
| AVG Volume (30 Days) | ★ 1.3M | 531.7K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.82 |
| EPS | 2.78 | ★ 10.88 |
| Revenue | ★ $8,068,000,000.00 | $3,105,638,000.00 |
| Revenue This Year | $1.59 | $7.96 |
| Revenue Next Year | $3.74 | $6.32 |
| P/E Ratio | $51.41 | ★ $36.30 |
| Revenue Growth | N/A | ★ 6.90 |
| 52 Week Low | $85.06 | $275.05 |
| 52 Week High | $161.00 | $423.56 |
| Indicator | XPO | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 61.33 |
| Support Level | $130.02 | $386.09 |
| Resistance Level | $142.64 | $403.80 |
| Average True Range (ATR) | 5.60 | 9.63 |
| MACD | 0.66 | -1.66 |
| Stochastic Oscillator | 82.98 | 53.55 |
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.